The Market Online Video

Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound

Recce Pharmaceuticals (ASX:RCE) has confirmed its completion of the latest study using its R327 anti-infective as…

Recce steps up defence ties with burn gel presentation at Military conference

Recce Pharma (ASX:RCE) has announced it's further boosting its role as an emerging defence company operating…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…